---
title: "Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| 5-HT | 5-hydroxytryptamine (serotonin) |
| 5-HT1A | Serotonin 1A receptor |
| 5-HT2A | Serotonin 2A receptor |
| 5-HT2B | Serotonin 2B receptor |
| 5-HT2C | Serotonin 2C receptor |
| 5D-ASC | 5 Dimensions of Altered States of Consciousness questionnaire |
| AAFP | American Academy of Family Physicians |
| AD | Anxiety disorders |
| AE | Adverse event |
| AESI | Adverse event of special interest |
| AFP | American Family Physician |
| AGS | American Geriatrics Society |
| AH | Antihistamines |
| AHFS | American Hospital Formulary Service |
| ANCOVA | Analysis of covariance |
| ANOVA | Analysis of variance |
| AOO | Age of onset |
| APA | American Psychiatric Association |
| ASEX | Arizona Sexual Experiences Scale |
| ASIR | Age-standardized incidence rate |
| ASPR | Age-standardized prevalence rate |
| AUC | Area under the concentration-time curve |
| AZA | Azapirones |
| BAI | Beck Anxiety Inventory |
| BAP | British Association for Psychopharmacology |
| BDI | Beck Depression Inventory |
| BLA | Basolateral amygdala |
| BMI | Body mass index |
| BP | Blood pressure |
| BZ | Benzodiazepines |
| C-SSRS | Columbia-Suicide Severity Rating Scale |
| CAM | Complementary and alternative medicine |
| CANMAT | Canadian Network for Mood and Anxiety Treatments |
| CBT | Cognitive behavioral therapy |
| CFR | Code of Federal Regulations |
| CGI-I | Clinical Global Impression-Improvement |
| CGI-S | Clinical Global Impression-Severity |
| CHD | Coronary heart disease |
| CI | Confidence interval |
| CLBP | Chronic low back pain |
| CMA | Centromedial amygdala |
| CMS | Centers for Medicare & Medicaid Services |
| CNS | Central nervous system |
| COI | Cost of illness |
| CPT | Current Procedural Terminology |
| CR | Controlled release |
| CrI | Credible interval |
| CSA | Controlled Substances Act |
| CSFQ-14 | Changes in Sexual Functioning Questionnaire, short form |
| CTIS | Clinical Trials Information System |
| CYP | Cytochrome P450 |
| CYP2D6 | Cytochrome P450 2D6 |
| DEA | Drug Enforcement Administration |
| DPNP | Diabetic peripheral neuropathic pain |
| DSM | Dosing session monitor |
| DSM-5 | Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition |
| DSM-IV | Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition |
| EMA | European Medicines Agency |
| EOP2 | End-of-phase 2 |
| EoSC | End-of-session checklist |
| EQ-5D-5L | EuroQol 5-Dimension 5-Level questionnaire |
| ER | Extended release |
| ES | Effect size |
| EU | European Union |
| FAS | Full analysis set |
| FDA | U.S. Food and Drug Administration |
| FM | Fibromyalgia |
| GAD | Generalized anxiety disorder |
| GAD-7 | Generalized Anxiety Disorder 7-item scale |
| GHC | General health component |
| GMR | Geometric mean ratio |
| GSI | Global Severity Index |
| HAM-A | Hamilton Anxiety Rating Scale |
| HAM-D | Hamilton Depression Rating Scale |
| HCP | Healthcare provider |
| HCPCS | Healthcare Common Procedure Coding System |
| HCRU | Healthcare resource utilization |
| HPPD | Hallucinogen persisting perception disorder |
| HR | Hazard ratio |
| HRA | Health Research Authority |
| HRQoL | Health-related quality of life |
| ICD-10 | International Classification of Diseases, 10th Revision |
| ICER | Institute for Clinical and Economic Review; incremental cost-effectiveness ratio |
| IDR | Incidence density ratio |
| ILAP | Innovative Licensing and Access Pathway |
| IND | Investigational New Drug application |
| IQR | Interquartile range |
| ISRCTN | International Standard Randomised Controlled Trial Number registry |
| ITT | Intention to treat |
| LS | Least squares |
| LSD | Lysergic acid diethylamide |
| LTI | Life-threatening illness |
| MADRS | Montgomery-Åsberg Depression Rating Scale |
| MBHR | Mental and Behavioral Health Registry |
| MCP-Mod | Multiple Comparison Procedure-Modelling |
| MD | Mean difference |
| MDD | Major depressive disorder |
| MDE | Major depressive episode |
| MDMA | 3,4-methylenedioxymethamphetamine |
| MDMA-AP | MDMA-assisted psychotherapy |
| MDPS | Mental and Substance Use Disorders Prevalence Study |
| MEPS | Medical Expenditure Panel Survey |
| MHC | Mental health component |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| MINI | Mini-International Neuropsychiatric Interview |
| MIPS | Merit-based Incentive Payment System |
| MMRM | Mixed-effects model for repeated measures |
| MRR | Mortality rate ratio |
| NCS-A | National Comorbidity Survey Adolescent Supplement |
| NCS-R | National Comorbidity Survey Replication |
| NDA | New Drug Application |
| NESARC | National Epidemiologic Survey on Alcohol and Related Conditions |
| NHIS | National Health Interview Survey |
| NHWS | National Health and Wellness Survey |
| NICE | National Institute for Health and Care Excellence |
| NNT | Number needed to treat |
| NSDUH | National Survey on Drug Use and Health |
| OA | Osteoarthritis |
| OCD | Obsessive-compulsive disorder |
| ODT | Orally disintegrating tablet |
| OOP | Out-of-pocket |
| OR | Odds ratio |
| PBM | Pharmacy benefit manager |
| PD | Panic disorder; pharmacodynamics |
| PGB | Pregabalin |
| PGI-C | Patient Global Impression of Change |
| PGI-S | Patient Global Impression of Severity |
| PHC | Physical health component |
| PK | Pharmacokinetics |
| PM | Poor metabolizer |
| PPS | Per protocol set |
| PTSD | Posttraumatic stress disorder |
| QALY | Quality-adjusted life year |
| QHP | Qualified healthcare professional |
| QTc | Corrected QT interval |
| RCT | Randomized controlled trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| RMP | Risk Management Plan |
| RR | Relative risk |
| RVU | Relative value unit |
| SAD | Social anxiety disorder |
| SAE | Serious adverse event |
| SAF | Safety set |
| SCID | Structured Clinical Interview for DSM |
| SCL-90-R | Symptom Checklist-90-Revised |
| SD | Standard deviation |
| SDS | Sheehan Disability Scale |
| SE | Standard error |
| SI | Suicidal ideation |
| SMD | Standardized mean difference |
| SNRI | Serotonin-norepinephrine reuptake inhibitor |
| SSRE | Sample size re-estimation |
| SSRI | Selective serotonin reuptake inhibitor |
| STAI | State-Trait Anxiety Inventory |
| STAI-G | State-Trait Anxiety Inventory, global score |
| TAU | Treatment as usual |
| TCA | Tricyclic antidepressant |
| TEAE | Treatment-emergent adverse event |
| TQT | Thorough QT |
| TRD | Treatment-resistant depression |
| UC | Usual care |
| UHB | University Hospital Basel |
| UI | Uncertainty interval |
| UK | United Kingdom |
| UM | Ultra-rapid metabolizer |
| US | United States |
| USAN | United States Adopted Name |
| USPSTF | U.S. Preventive Services Task Force |
| VAS | Visual analog scale |
| WFSBP | World Federation of Societies of Biological Psychiatry |
| WL | Waitlist |
| WPAI-SHP | Work Productivity and Activity Impairment Questionnaire: Specific Health Problem |
| XR | Extended release |

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
